Why Is Pfizer Stock Paying You So Much To Wait?
Yahoo · 14 de sept de 2026
Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds…
CEDEAR BMY
Bristol-Myers Squibb Company
Sí, existe CEDEAR de BMY en Argentina. Operás bajo el ticker BMY en BYMA, con ratio 3:1 respecto a la acción en NYSE.
Empresa subyacente
HealthcareDrug Manufacturers - General
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
- País
- United States
- Empleados
- 32.500
- Sitio web
- bms.com
Precio histórico
Últimos 203 días · 12/11/25 — 14/09/26
+40.51%
Cotización y datos
NYSERatio 3:1 · Subyacente BMY
CEDEAR (ARS)
Precio
$ 33.840
Var. %
-0,82%
Volumen operado
1.100
Subyacente (USD)
Precio BMY
US$ 63,80
Teórico (precio / ratio)
BMY ÷ 3
US$ 21,27
Dólar MEP (BMYD)
Preguntas frecuentes
¿Existe CEDEAR de BMY en Argentina?
Sí, existe el CEDEAR de BMY (Bristol-Myers Squibb Company) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es BMY.
¿Cuál es el ticker del CEDEAR de Bristol-Myers Squibb Company?
El ticker del CEDEAR de Bristol-Myers Squibb Company en Argentina es BMY. La acción subyacente cotiza en NYSE con el símbolo BMY.
¿Cuál es el ratio del CEDEAR BMY?
El CEDEAR BMY tiene un ratio de 3:1. Eso significa que 3 CEDEARs equivalen a 1 acción de BMY.
¿Cuánto vale el CEDEAR BMY hoy?
El CEDEAR BMY cotiza hoy a $ 33.840 en pesos argentinos, con una variación diaria de -0,82%.
¿Cuánto vale la acción BMY en dólares?
La acción subyacente BMY (Bristol-Myers Squibb Company) cotiza a US$ 63,80 en su mercado de origen (NYSE).
Noticias
3 Healthcare Stocks That Fall Short
Yahoo · 14 de sept de 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements…
Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
Yahoo · 14 de sept de 2026
DelveInsight's Bispecifics Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current trea…
